These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2578093

  • 1. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1985 Jan; 45(1):213-6. PubMed ID: 2578093
    [Abstract] [Full Text] [Related]

  • 2. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1989 Jun 15; 49(12):3310-3. PubMed ID: 2470504
    [Abstract] [Full Text] [Related]

  • 3. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
    Bizanek R, Chowdary D, Arai H, Kasai M, Hughes CS, Sartorelli AC, Rockwell S, Tomasz M.
    Cancer Res; 1993 Nov 01; 53(21):5127-34. PubMed ID: 7693331
    [Abstract] [Full Text] [Related]

  • 4. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
    Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5638-43. PubMed ID: 6437671
    [Abstract] [Full Text] [Related]

  • 5. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
    Rockwell S, Keyes SR, Sartorelli AC.
    Anticancer Res; 1989 Dec 01; 9(4):817-20. PubMed ID: 2479329
    [Abstract] [Full Text] [Related]

  • 6. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1985 Aug 01; 45(8):3642-5. PubMed ID: 3926306
    [Abstract] [Full Text] [Related]

  • 7. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
    Rockwell S, Keyes SR, Sartorelli AC.
    Radiat Res; 1988 Oct 01; 116(1):100-13. PubMed ID: 3186923
    [Abstract] [Full Text] [Related]

  • 8. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo.
    Rauth AM, Mohindra JK, Tannock IF.
    Cancer Res; 1983 Sep 01; 43(9):4154-8. PubMed ID: 6409398
    [Abstract] [Full Text] [Related]

  • 9. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.
    Rockwell S, Keyes SR, Sartorelli AC.
    Cancer Res; 1988 Oct 01; 48(19):5471-4. PubMed ID: 2458178
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM, Sartorelli AC.
    Cancer Res; 1986 Aug 01; 46(8):3939-44. PubMed ID: 3089583
    [Abstract] [Full Text] [Related]

  • 11. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
    Pritsos CA, Sartorelli AC.
    Cancer Res; 1986 Jul 01; 46(7):3528-32. PubMed ID: 3011250
    [Abstract] [Full Text] [Related]

  • 12. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET, Kelley M, Rockwell S.
    Cancer Chemother Pharmacol; 2004 Jan 01; 53(1):43-50. PubMed ID: 14574460
    [Abstract] [Full Text] [Related]

  • 13. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
    Rockwell S.
    J Natl Cancer Inst; 1983 Oct 01; 71(4):765-71. PubMed ID: 6413743
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC.
    Adv Enzyme Regul; 1985 Oct 01; 23():291-307. PubMed ID: 3934922
    [Abstract] [Full Text] [Related]

  • 15. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
    Pritsos CA, Keyes SR, Sartorelli AC.
    Cancer Biochem Biophys; 1989 Oct 01; 10(4):289-98. PubMed ID: 2559790
    [Abstract] [Full Text] [Related]

  • 16. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
    Kennedy KA, Rockwell S, Sartorelli AC.
    Cancer Res; 1980 Jul 01; 40(7):2356-60. PubMed ID: 7388797
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
    Kim SY, Rockwell S.
    Oncol Res; 1995 Jul 01; 7(5):39-47. PubMed ID: 8534933
    [Abstract] [Full Text] [Related]

  • 18. Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo.
    Rockwell S, Keyes SR, Sartorelli AC.
    Cancer Chemother Pharmacol; 1989 Jul 01; 24(6):349-53. PubMed ID: 2477164
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
    Rockwell S, Kim SY.
    Oncol Res; 1995 Jul 01; 7(1):39-47. PubMed ID: 7549043
    [Abstract] [Full Text] [Related]

  • 20. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
    Rockwell S, Nierenburg M, Irvin CG.
    Cancer Treat Rep; 1987 Oct 01; 71(10):927-34. PubMed ID: 3652056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.